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Abstract
Introduction Lung cancer is the leading cause of cancer-
related death worldwide. The discovery of new biomarkers
could aid early diagnosis and monitoring of recurrence
following tumor resection.
Methods We have prospectively collected serum from 97
lung cancer patients undergoing surgery with curative intent
and compared their serum proteomes with those of 100
noncancer controls (59 disease-free and 41 with a range of
nonmalignant lung conditions). We initially analyzed serum
from 67 lung cancer patients and 73 noncancer control
subjects by surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry using immobilized metal
affinity capture ProteinChip arrays and subsequently vali-
dated our findings with an independent analysis of 30 lung
cancer patients and 27 noncancer subjects.
Results The data from both experiments show many
significant differences between the serum proteomes of
lung cancer patients and nondiseased control subjects, and
a number of these polypeptides have been identified.
However, the profiles of patients with benign lung
diseases resembled those of lung cancer patients such that
very few significant differences were found when these
cohorts were compared.
Conclusions This report provides clear evidence of the
need to account for the confounding effects of benign
diseases when designing lung cancer serum biomarker
discovery projects.
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Abbreviations
ITIH4 Inter-alpha-trypsin inhibitor heavy chain 4
LC–MS/MS On-line liquid chromatography electrospray
tandem mass spectrometry
MALDI Matrix-assisted laser desorption/ionization
RP-HPLC Reverse-phase high-performance liquid
chromatography
SELDI Surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry
Introduction
Lung cancer is the leading cause of cancer-related mortality
[1]. The majority of cases present with advanced disease, and
only 20% are potentially curable by surgical resection [2, 3].
Current methods of lung cancer detection in symptomatic
individuals are based on expensive and labor-intensive
clinical and radiological assessments. Current serum markers
are insufficiently sensitive or specific for screening and
diagnosis. The discovery and validation of new biomarkers
to aid early diagnosis and surveillance after tumor resection
is a priority.
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Surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI) is a biomarker discovery
tool that has been used by many groups, including ourselves,
to examine the serum proteome of a wide range of cancer
types in comparison to noncancer controls, e.g., [4–9].
SELDI uses a combination of retentate chromatography
and matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry to generate “proteomic profiles”. The
peak intensities in these profiles are then analyzed for
significant differences between patient cohorts and used to
generate class prediction models to discriminate between
the cancer and noncancer patients. Once the discriminato-
ry peaks have been selected, the proteins responsible for
the peaks can be purified, digested, and identified by on-
line liquid chromatography electrospray tandem mass
spectrometry (LC–MS/MS). Identification of the proteins
responsible for discriminatory SELDI peaks may allow
antibody-based assays to be developed to assay these
potential biomarkers.
Several groups have used SELDI serum analysis to
search for diagnostic markers for nonsmall cell lung cancer
but most have compared cancer patients to nondiseased
control subjects [8, 10–13]. Han et al. have reported that
SELDI can distinguish between patients with small cell
lung cancer and patients with pneumonia [14]. Yildiz et al.
included diseased controls matched across their multisite
case-control MALDI analysis of 288 patient sera [15];
however, the sensitivity and specificity of their class
prediction model was lower than in the single-site studies
utilizing nondiseased controls. MALDI profiling of serum
has also been shown to be able to predict the sensitivity of
advanced nonsmall cell lung cancer to epidermal growth
factor receptor inhibitors [16].
We have now used SELDI to analyze the samples
collected in the first phase of a prospective serum collection
aimed at characterizing the serum proteomes of patients
with resectable nonsmall cell lung cancer, disease-free
control subjects, and patients with nonmalignant lung
conditions. The data show that similar proteomic differ-
ences are detected between the sera of nondiseased
individuals and cancer patients as between nondiseased
individuals and benign disease controls. This study shows
that the use of appropriate controls in serum proteomics is
essential to avoid false-positive results.
Experimental Procedures
Patients and Serum Preparation
In a study specifically designed to identify lung cancer-related
biomarkers, patients referred to Birmingham Heartlands
Hospital for surgical resection of lung cancer, patients with a
suspicious lung mass, and patients without lung cancer were
recruited between January 2005 and April 2008. Informed
consent was obtained from all participants using a protocol
approved by the local ethics committee. The study was
approved by the National Cancer Research Network. Sera
were obtained from 97 patients in whom lung cancer was
ultimately confirmed histologically; these constitute the
cohort of cancer patients (33 female, 64 male, mean age
65.9 years) including 48 squamous cell carcinoma, 35
adenocarcinoma, 14 other nonsmall cell carcinoma with a
stage distribution of 54 in stage I, 14 in stage II, 25 in stage III,
and four stage IV. The control group comprised 100 patients
(39 female, 61 male, mean age 63.2 years) of which 13
suspected of having lung cancer preoperatively underwent
surgery and had benign thoracic pathologies (carcinoid,
hamartoma), ten who underwent surgery for end-stage lung
conditions (interstitial lung disease, end-stage emphysema),
and 20 who had surgery for pleura pulmonary sepsis. Fifty-
nine patients were recruited as nonpulmonary controls
attending the same hospital for a range of routine blood tests.
Patient information is summarized in Table 1.
Venous blood was taken into standard collection tubes
with clot activator and allowed to clot for 1–2 h prior to
20 min centrifugation at 3,000×g. The supernatant was
aspirated and placed in six 200-μl aliquots prior to storage
at −80°C. Each sample was given a unique identification
number to mask the identity (patient/control) from the
laboratory staff performing the SELDI analysis.
SELDI Analysis
Sera were analyzed in duplicate on Cu2+-loaded immobi-
lized metal affinity capture (IMAC) ProteinChip arrays
using a Protein Biological System IIc time-of-flight mass
spectrometer equipped with an autoloader (BioRad). All
samples were randomized with respect to position in the 96-
well bioprocessors used to process the ProteinChip arrays.
Sera were processed, spectra acquired, and peak intensities
extracted exactly as previously described [6, 7]. Statistically
significant differences in peak intensity between patient
cohorts were identified by Wilcoxon test.
Peak Identification
Serum samples rich in the peak of interest were diluted
fourfold with 9 M urea, 2% 3-[(3-cholamidotropyl)
dimethylammonio]-1-prop-anesulphonate, 50 mM Tris/
HCl (pH 9.0), and applied to Q Ceramic HyperD F anion
exchange resin (Pall). Proteins were eluted from the resin
using buffers at decreasing pH (7, 5, 4, and 3). The fraction
containing the SELDI peak of interest was then subjected to
C4 and/or C18 reverse-phase high-performance liquid
chromatography (RP-HPLC) using 4.6×250 mm columns
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(Phenomenex) and 0–80% acetonitrile gradients in 0.1%
trifluoroacetic acid. The HPLC fractions were analyzed by
MALDI (accurate masses were obtained for many of the
SELDI peaks by reading the SELDI chips in a Perkin-
Elmer ProTOF 2000 orthogonal time-of-flight MALDI).
Fractions containing peaks of interest were lyophilized and
either dissolved in 3% formic acid for LC–MS/MS without
trypsinization or loading buffer for sodium dodecyl sulfate
polyacrylamide gel electrophoresis (12% NuPage gels with
MES buffer, Invitrogen). Gel bands were excised, reduced,
alkylated, and digested with sequencing grade trypsin
(Promega) as described previously [6, 7, 17]. Peptides were
analyzed by LC–MS/MS using a ThermoFinnigan LCQ
Deca XP Plus Ion-Trap linked directly to LC Packings/
Dionex Ultimate nanobore HPLC system. MS/MS data
were searched against a database of nonredundant human
protein sequences extracted from IPI human database
(version 3.23) using SEQUEST. Mass tolerances were
±1.5 Da for parent ions and 0.0 for MS/MS fragments.
Data were filtered using Xcorr values of 1.5, 2, and 2.5 for
singly, doubly, and triply charged parent ions, respectively,
and only first hits were considered.
Results
Initial SELDI Survey
SELDI profiles were obtained for serum samples from 67
lung cancer patients and 73 noncancer controls (29 of the
controls had benign lung diseases as detailed in Table 1).
Wilcoxon tests revealed 46 significant differences in peak
intensity between the cancer patients and the noncancer
controls (p<0.01). However, when the noncancer cohort
was divided into patients with benign lung diseases or no
lung disease, a different picture emerged: There were 62
significant differences between lung cancer patients and
patients without lung disease but only four significant
differences between lung cancer patients and patients with
benign lung diseases (m/z 1,544, 1,573, 6,631, 14,070).
There were also no significant differences between patients
with early (stage I/II) and late stage (stage III/IV) disease
and only one (m/z 5,367) between patients with adenocar-
cinoma and squamous cell carcinoma. As can be seen from
the fold changes shown in Table 2, many of the differences
between the nondiseased controls and the diseased controls
are similar to those between the nondiseased controls and
the cancer patients. Upon subdividing the diseased controls,
Wilcoxon tests revealed seven significant differences
between the benign tumor cohort and the cancer cohort
(m/z 3,531, 4,138, 5,920, 6,682, 6,691, 14,070, 88,100) but
none between lung cancer and end-stage lung disease or
pleuropulmonary sepsis (p<0.01).
Peak Identifications
We have purified and identified ten of the polypeptides
underlying the SELDI peaks that differ significantly in
intensity between nondiseased controls and lung cancer
patients (Table 3). Most of the data used in the identifica-
Table 1 Patient information
Number of patients Age (mean) Gender (F/M) Staging Details
Discovery survey Lung cancer 67 65.3 23/44 Stage I, 34 32 squamous
Stage II, 10 25 adenocarcinoma
Stage III, 21 10 other NSCLC
Stage IV, 2
Benign controls 29 60.5 11/18 – 8 benign tumors
6 end stage lung disease
15 pleuropulmonary sepsis
Disease-free controls 44 65.0 14/30 – –
Validation survey Lung cancer 30 69.0 10/20 Stage I, 20 16 squamous
Stage II, 4 10 adenocarcinoma
Stage III, 4 4 other NSCLC
Stage IV, 2
Benign controls 12 58.5 5/7 – 5 benign tumors
4 end-stage lung disease
3 pleuropulmonary sepsis
Disease-free controls 15 58.0 9/6 – –
The table shows the composition of the patient cohorts in the “discovery” and “validation” experiments
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tions (MS/MS spectra and immunoSELDI) are presented in
“Supplemental Information”. Two of these peaks at m/z
6,431 and 6,631, we have previously identified as apolipo-
protein C1 and N-terminally truncated apolipoprotein C1 [7]
and the identities were confirmed by immunoSELDI. The
protein producing a peak at m/z 14,690 was purified,
digested, and identified by LC–MS/MS (two tryptic peptides,
18% sequence coverage) as lysozyme C. This was confirmed
by immunoSELDI. A pair of peaks at m/z 13,880 and 14,070
copurified and were identified as transthyretin (five tryptic
peptides giving 58% sequence coverage). The two peaks
most likely correspond to the cysteinylated and glutathiony-
lated transthyretin that have been described previously [18].
A peak with m/z 5,080 was purified and trypsinized,
and LC–MS/MS identified a single fully tryptic peptide
(K.A81LGISPFHEHAEVVFTANDSGPR103.R) from
transthyretin (3+ ion, Xcorr 5.37). An IMAC ProteinChip
array was analyzed in a ProTOF 2000 MALDI providing
an accurate monoisotopic mass for the m/z 5,080 SELDI
peak of 5,077.67 Da, which matches the calculated mass
from A81 to the C terminus of transthyretin (5,077.57 Da,
monoisotopic H+ ion). Further data analysis also identified
a partially tryptic peptide, A.A108LLSPYSYST-
TAVVTNPK126.E, located C-terminal to R103, giving a
total of 94% sequence coverage of the 5,077.67 fragment
of transthyretin. No peptides derived from transthyretin N-
terminal to A81 were detected. The identification was
confirmed by immunoSELDI using a polyclonal trans-
thyretin antibody. In patients with an elevated m/z 5,080
SELDI peak, the intensity of the intact transthyretin peaks
was decreased, consistent with the former being a
proteolytic fragment of the latter (Fig. 1).
Two peaks with m/z 3,273 and 3,289 copurified by anion
exchange/RP-HPLC and were identified from one fully
Table 3 Polypeptide identifications
m/z ratio p value (Wilcoxon) Fold change Polypeptide identification
Experiment 1 Experiment 2 Experiment 1 Experiment 2
1,778 4.9×10−5 2.5×10−6 3.5 11 Fragment of complement C3f (SKITHRIHWESASLL)
1,865 6.5×10−4 2.4×10−7 2.1 46 Fragment of complement C3f (SSKITHRIHWESASLL)
3,273 4.2×10 −3 1.6×10−4 1.8 7.7 Fragment of ITIH 4
(MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF)
3,289 9.8×10−6 1.4×10−4 2.4 8.9 Fragment of ITIH 4
(M*NFRPGVLSSRQLGLPGPPDVPDHAAYHPF)
5,080 1.6×10−8 4.1×10−3 1.7 2.2 Transthyretin fragment
6,431 5.1×10−3 2.0×10−2 0.67 0.63 N-terminal truncated apolipoprotein C1
6,631 2.5×10−4 3.5×10−3 0.55 0.60 Apolipoprotein C1
13,880 6.8×10−3 7.3×10−3 0.85 0.685 Transthyretin
14,070 1.3×10−3 3.5×10−4 0.71 0.64 Transthyretin
14,690 3.0×10−6 1.8×10−4 0.62 0.64 Lysozyme C
p values are shown for cancer versus disease-free controls in SELDI experiments 1 and 2. Fold changes indicate the median of the cancer cohort
divided by the median of the disease-free controls












5,080 1.64E−08 0.071 1.74 1.43
15,140 5.20E−07 0.019 0.52 0.82
3,521 6.89E−07 0.091 2.23 1.50
6,672 9.09E−07 0.053 0.57 0.88
6,681 1.57E−06 0.071 0.57 0.87
14,690 3.02E−06 0.033 0.62 0.84
131,600 6.59E−06 0.049 0.67 0.86
17,090 6.98E−06 0.024 1.70 1.32
3,289 9.78E−06 0.175 2.39 1.50
4,213 1.52E−05 0.029 0.60 0.81
Table 2 Significant differences
between lung cancer patients
and nondiseased and diseased
controls
p values were calculated by
Wilcoxon test and fold changes
indicate the median of one
cohort divided by the median of
the other. Peaks in italics have
been identified
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tryptic peptide (R.M658NFRPGVLSSR668.Q) and one par-
tially tryptic peptide (R.P661GVLSSRQLGLPGPPDVPDH
AAYHPF687.R) from inter-alpha-trypsin inhibitor heavy
chain 4 precursor (ITIH4). Including methionine oxidation
as a possible modification also provided a hit indicating that
the peak at m/z 3,289 contained the oxidized form of this
sequence. Hence, we have 100% sequence coverage of this
30 residue fragment of ITIH4, M658NFRPGVLSSRQLGLP
GPPDVPDHAAYHPF687, calculated mass 3,272.64 or
3,288.64 Da with methionine oxidation (masses measured
by MALDI, 3,272.68 and 3,288.70).
The peptides underlying SELDI peaks with m/z 1,778 and
1,865 were purified by anion exchange and reverse-phase
HPLC and subjected to LC–MS/MS without digestion. The
m/z 1,778 and m/z 1,865 peptides were identified as truncated
versions of complement C3f: SKITHRIHWESASLL (2+ ion,
Xcorr =2.92) and SSKITHRIHWESASLL (2+ ion,
Xcorr =3.20). Figure 2 shows the accurate mass determina-
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Fig. 1 The relationship between the intensity of the m/z 5,080
transthyretin fragment and the parent protein (m/z 13,880). Lung
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Fig. 2 Identification of
complement C3f fragments. A
SELDI chip was analaysed in a
ProTOF200 MALDI to obtain
acurate monoisotopic masses
(top spectrum). Following
purification, the peptides were
identified by LC–MS/MS
(middle and bottom spectra)
152 Clin Proteom (2009) 5:148–155
for both peptides showing a common series of y-ions and
b-ions that are different by the mass of a serine residue.
Validation SELDI Survey
Independent validation was performed on samples collected
after the initial experiment outlined above was completed.
Sera from 30 lung cancer patients and 27 noncancer
controls (12 with benign lung diseases) were analyzed
using identical procedures. We found 44 significant differ-
ences between lung cancer and noncancer (no-disease and
benign lung disease) controls, 86 significant differences
between lung cancer and nondiseased controls but no
significant differences between lung cancer patients and
patients with benign lung disease. Although we found
significant systematic differences between the two SELDI
datasets (data not shown), many of the significant differ-
ences between lung cancer patients and disease-free
controls were common to both experiments: Of the 62
peaks with p<0.01 for cancer versus disease-free in
experiment 1, 41 also had p<0.01 and changed in the same
direction in experiment 2 with p<0.01. This demonstrates
both that SELDI is sufficiently reproducible to detect
proteomic differences between patient groups on separate
Fig. 3 Box plots of SELDI
peak intensities of three identi-
fied polypeptides. Data are
shown left to right: experiment 1
disease-free control, disease
control, cancer; experiment 2
disease-free control, disease
control, cancer. Solid bars rep-
resent medians, boxes lower and
upper quartiles with outliers
shown as open circles
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occasions and that many of the same differences occur in
independent sets of patients.
The intensities of three peaks that differ significantly
between cancer patients and nondiseased controls in both
SELDI experiments and that have been identified are
shown in Fig. 3. These data demonstrate that the changes
detected in lung cancer and benign diseases are similar and
can be detected reproducibly.
Discussion
The experiments presented here show a number of SELDI
peaks that are significantly increased or decreased in
intensity in the serum of lung cancer patients compared to
nondisease controls, as reported previously by several
groups [10–13]. However, when the noncancer controls
were considered as two distinct groups, those with and
without benign lung diseases, the vast majority of differ-
ences were only seen in the nondisease controls. The
differences between nondisease controls and benign disease
controls samples resembled the differences between the
nondisease controls and the lung cancer patients.
Nonmalignant disease controls have been included in a
number of SELDI cancer biomarker studies and confound-
ing effects have either not been reported (presumably
because they were not investigated or found to be
negligible) or have only partially obscured cancer specific
effects, e.g., [19–21]. We now report that some benign
conditions can mimic the effect of cancer, a significant
finding when one considers that much of the SELDI-based
biomarker discovery literature utilizes only healthy con-
trols, potentially generating many false leads. Although
based on a very small number of patients (Table 1), some
significant differences were seen between patients with
benign tumors and those with lung cancer, and these might
have clinical utility in making this distinction in the absence
of confounding conditions.
Few previous SELDI/MALDI serum profiling studies of
lung cancer have identified the polypeptides underlying
disease associated peaks. However, it is known that despite
the retentate chromatography step and the selective detec-
tion of the low molecular weight proteome, most of the
peaks in SELDI spectra of serum arise from abundant
serum proteins and their breakdown products [22, 23].
Thus, it is not surprising that the polypeptides underlying
SELDI peaks differing significantly in intensity between
lung cancer patients and nondiseased controls are also
abundant serum proteins or fragments thereof. The SELDI
intensities of the protein fragments that we have identified
are all increased by lung disease, most likely because they
are present at increased concentrations [24, 25], possibly
due to altered proteolytic activity in these patients. Trans-
thyretin, a thyroxine transporting protein synthesized
predominantly in the liver, is a negative acute phase protein
and decreases in the serum of patients with various cancers
including ovarian [9, 26], pancreatic [27], and lung [28].
However, we now provide evidence that the decrease in
intact transthyretin in patients with lung disease may be at
least partially due to proteolytic degradation (Fig. 1). We
also found the SELDI intensity of intact and truncated
forms of apolipoprotein C1 and lysozyme C to be decreased
in the serum of lung cancer patients. Both proteins are
unlikely to be emanating directly from tumors and are
altered in a number of other conditions, e.g. [7, 29]. In our
study, the proteomic changes may well reflect the host
response to the tumor, and it is perhaps not surprising that
these proteins lack tumor specificity although cancer-type
specific variants of transthyretin have been reported,
including cysteine modifications and truncations [27, 30].
Several of the protein cleavages and modifications that we
find in both the cancer patients and patients with benign lung
diseases have previously been proposed as potential tumor
biomarkers [30–32]. Our work shows that these modifica-
tions of abundant serum proteins are also associated with
benign lung disease although we cannot rule out that more
in-depth peptidome profiling might be able to discriminate
between the effects of lung cancer and other lung diseases.
In conclusion, our SELDI data show that proteomic
changes can be detected in the serum of lung cancer
patients, and we have identified a number of the proteins
involved. These changes are not specific to lung cancer but
can also arise from nonmalignant lung conditions and
unfortunately are not likely to prove useful as cancer
biomarkers. This demonstrates that it is essential to the
design of future proteomic cancer biomarker studies,
regardless of the proteomic methodology employed, to
include appropriate control subjects with a range of
nonmalignant conditions to ensure the specificity of any
markers detected. Indeed, it should be considered that the
recruitment of appropriate noncancer controls is as impor-
tant as that of the cancer patients.
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